The global Veterinary Pharmacovigilance market size is predicted to grow from US$ 985 million in 2025 to US$ 2162 million in 2031; it is expected to grow at a CAGR of 14.0% from 2025 to 2031.

Pharmacovigilance (PV) is a science relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. It ensures the monitoring of adverse drug reactions (ADRs) throughout the life period of a drug.

Veterinary pharmacovigilance concerns monitoring, evaluating, and improving the safety of veterinary medicines, particularly regarding adverse events in animals and human beings. It also involves the collection of information on adverse events due to off-label use and investigations of the withdrawal period and potential environmental problems.

The industry is driven by the need to ensure that animal health products are safe for consumption by animals and do not pose risks to human health. Competition in the market is intense as companies strive to gain a competitive advantage through innovative solutions and pricing.

Key trends include the adoption of new technologies such as electronic reporting systems and data analytics tools that enable efficient, accurate reporting and monitoring of adverse events.

Segmentation by Type:

• In-house
• Contract Outsourcing

Segmentation by Application:

• Companion Animals
• Farm Animals

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage:

• Accenture
• ArisGlobal
• Azierta Contract Science Support Consulting
• Biologit
• Ennov
• Indivirtus
• Knoell
• Oy Medfiles Ltd.
• Pharsafer Associates Limited
• Sarjen Systems Pvt. Ltd.

Key Questions Addressed in this Report: